Hormone replacement therapy and risk of breast cancer: the role of progestins

  title={Hormone replacement therapy and risk of breast cancer: the role of progestins},
  author={Claudia Irene Stahlberg and Anette T{\o}nnes Pedersen and Elsebeth Lynge and Bent S. Ottesen},
  journal={Acta Obstetricia et Gynecologica Scandinavica},
Epidemiological studies have shown an increased risk of breast cancer associated with the use of hormone replacement therapy (HRT). This notion is mostly based on studies from the USA. During the last decades unopposed estrogen treatment has been used to a lesser extent, whereas the combined estrogen‐progestin treatment regimen is now prescribed worldwide. In the USA the predominant compounds are conjugated estrogens and medroxyprogesterone‐acetate, whereas oestradiol combined with testosterone… 

Pregnancy, progesterone and progestins in relation to breast cancer risk

E2 + norethisterone promotes the PI3K–AKT pathway via PGRMC1 to induce breast cancer cell proliferation

Evidence is found that progesterone receptor membrane component 1 promotes estradiol (E2) + norethisterone (NET)-induced breast cancer proliferation through activation of the phosphatidylinositol-3-kinase (PI3K)–AKT pathway.

An investigation of basic science and clinical research methodologies to benefit clinical practice

The thesis concludes by suggesting strategies to augment the research methodological approaches evaluated in this thesis in order to fulfill the aim of benefitting clinical practice.

Advances in the understanding and treatment of ovarian cancer

  • J. Morrison
  • Medicine, Biology
    The journal of the British Menopause Society
  • 2005
In England and Wales, ovarian cancer is responsible for more deaths than all other gynaecological cancers combined and most women will relapse and the five-year survival rate is 20–30%.



More about: effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin.

A comparison between the only two studies where the influence of sequential estrogen plus progestin replacement therapy (SEPRT) and continuous combined estrogen plusprogestin replacement Therapy (CCRT) has been explored is made.

Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk.

The data suggest that the estrogen-progestin regimen increases breast cancer risk beyond that associated with estrogen alone, and were evident for the majority of invasive tumors with ductal histology and regardless of extent of invasive disease.

Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin.

This study provides strong evidence that the addition of a progestin to HRT enhances markedly the risk of breast cancer relative to estrogen use alone, and has important implications for the risk-benefit equation for HRT in women using CHRT.

A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer.

To quantify the effect of estrogen replacement therapy on breast cancer risk, we combined dose-response slopes of the relative risk of breast cancer against the duration of estrogen use across 16

Risks of breast and endometrial cancer after estrogen and estrogen–progestin replacement

Long-term recent use of estrogen–progestin combined replacement therapy may increase the risk of breast cancer, an increase that can be reduced or perhaps avoided by adding progestins.

Estrogen and estrogen plus progestin act directly on the mammary gland to increase proliferation in a postmenopausal mouse model

It is reported that responses of early and late postmenopausal mice to implanted hormones were the same as those observed previously with systemically administered hormones, and EGF may determine the sensitivity of the mammary gland to E and E+P in late post menopause and at puberty.

Hormone Replacement Therapy and Breast Cancer: A Qualitative Review

Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer.

  • Medicine
  • 1997
Of the many factors examined that might affect the relation between breast cancer risk and use of HRT, only a woman's weight and body-mass index had a material effect: the increase in the relative risk of breast cancer associated with long durations of use in current and recent users was greater for women of lower than of higher weight or body- mass index.